Equities Analysts Set Expectations for Genocea Biosciences Inc’s FY2018 Earnings (GNCA)
Genocea Biosciences Inc (NASDAQ:GNCA) – Equities researchers at Cantor Fitzgerald issued their FY2018 earnings per share (EPS) estimates for shares of Genocea Biosciences in a research report issued to clients and investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the biotechnology company will earn ($0.59) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $5.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Genocea Biosciences’ FY2019 earnings at ($0.65) EPS.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Friday, February 16th. The biotechnology company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.03.
Genocea Biosciences (NASDAQ GNCA) opened at $1.24 on Friday. The company has a market capitalization of $105.64, a PE ratio of -0.63 and a beta of 1.31. Genocea Biosciences has a 12-month low of $0.79 and a 12-month high of $7.29. The company has a debt-to-equity ratio of -1.26, a current ratio of 0.83 and a quick ratio of 0.83.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Genocea Biosciences by 13.9% in the second quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after purchasing an additional 104,790 shares during the last quarter. Northern Trust Corp lifted its stake in Genocea Biosciences by 642.9% in the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after purchasing an additional 265,328 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Genocea Biosciences by 11.5% in the second quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 2,300 shares during the last quarter. Schwab Charles Investment Management Inc. bought a new stake in Genocea Biosciences in the second quarter worth about $257,000. Finally, TIAA CREF Investment Management LLC bought a new stake in Genocea Biosciences in the second quarter worth about $404,000. 10.29% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/03/11/equities-analysts-set-expectations-for-genocea-biosciences-incs-fy2018-earnings-gnca.html.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.